Download PDF
Semin intervent Radiol 2023; 40(06): 536-543
DOI: 10.1055/s-0043-1777747
Review Article

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

McKenzie J. White
1   Department of Surgery, University of Minnesota, Minneapolis, Minnesota
,
Eric H. Jensen
1   Department of Surgery, University of Minnesota, Minneapolis, Minnesota
2   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
,
David G. Brauer
1   Department of Surgery, University of Minnesota, Minneapolis, Minnesota
2   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The surgical management of primary and secondary liver tumors is constantly evolving. Patient selection, particularly with regard to determining resectability, is vital to the success of programs directed toward invasive treatments of liver tumors. Particular attention should be paid toward determining whether patients are best served with surgical resection or ablative therapies. A multidisciplinary approach is necessary to provide optimal care to patients with liver malignancy.

Keywords

liver resection - liver ablation - liver-directed therapy - surgery - hepatocellular carcinoma - liver metastases


Publication History

Article published online:
24 January 2024

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356 (15) 1545-1559
    CrossrefPubMedGoogle Scholar
  • 2 Couinaud C. Lobes et segments hépatiques: notes sur l'architecture anatomiques et chirurgicale du foie [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver ]. Presse Med (1893). 1954; 62 (33) 709-712
    PubMedGoogle Scholar
  • 3 Strasberg SM, Belghiti J, Clavien PA. et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford) 2000; 2 (03) 333-339
    CrossrefPubMedGoogle Scholar
  • 4 Wakabayashi G, Cherqui D, Geller DA. et al. The Tokyo 2020 terminology of liver anatomy and resections: updates of the Brisbane 2000 system. J Hepatobiliary Pancreat Sci 2022; 29 (01) 6-15
    CrossrefPubMedGoogle Scholar
  • 5 Pulitano C, Crawford M, Joseph D, Aldrighetti L, Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. J Surg Oncol 2014; 110 (04) 445-450
    CrossrefPubMedGoogle Scholar
  • 6 Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137 (06) 675-680 , discussion 680–681
    CrossrefPubMedGoogle Scholar
  • 7 Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1271-1280
    CrossrefPubMedGoogle Scholar
  • 8 Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010; 102 (08) 960-967
    CrossrefPubMedGoogle Scholar
  • 9 Truant S, Baillet C, Gnemmi V. et al. The impact of modern chemotherapy and chemotherapy-associated liver injuries (CALI) on liver function: value of 99mTc-labelled-mebrofenin SPECT-hepatobiliary scintigraphy. Ann Surg Oncol 2021; 28 (04) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 10 Wang LJ, Yan XL, Li J, Wang K, Xing BC. Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis. Cancer Manag Res 2020; 12: 3237-3245
    CrossrefPubMedGoogle Scholar
  • 11 Chapelle T, Op De Beeck B, Huyghe I. et al. Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?. HPB (Oxford) 2016; 18 (06) 494-503
    CrossrefPubMedGoogle Scholar
  • 12 Primavesi F, Maglione M, Cipriani F. et al. E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy. Br J Surg 2023; 110 (10) 1331-1347
    CrossrefPubMedGoogle Scholar
  • 13 Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
    CrossrefPubMedGoogle Scholar
  • 14 Kim DY, Park BJ, Kim YH. et al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol 2015; 38 (05) 495-501
    CrossrefPubMedGoogle Scholar
  • 15 Hamoui N, Ryu RK. Hepatic radioembolization complicated by fulminant hepatic failure. Semin Intervent Radiol 2011; 28 (02) 246-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Khan A, Sayles HR, Dhir M. Liver resection after Y-90 radioembolization: a systematic review and meta-analysis of perioperative morbidity and mortality. HPB (Oxford) 2022; 24 (02) 152-160
    CrossrefPubMedGoogle Scholar
  • 17 Shindoh J, Tzeng CWD, Aloia TA. et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013; 20 (08) 2493-2500
    CrossrefPubMedGoogle Scholar
  • 18 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19 (13) 4287-4299
    CrossrefPubMedGoogle Scholar
  • 19 LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012 . Irinotecan. Published online April 27, 2018. Accessed October 19, 2023 at: https://www.ncbi.nlm.nih.gov/books/
    PubMedGoogle Scholar
  • 20 Han J, Zhang J, Zhang C. Irinotecan-induced steatohepatitis: current insights. Front Oncol 2021; 11: 754891
    CrossrefPubMedGoogle Scholar
  • 21 Gaba RC, Lewandowski RJ, Kulik LM. et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16 (06) 1587-1596
    CrossrefPubMedGoogle Scholar
  • 22 Shindoh J, Truty MJ, Aloia TA. et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216 (02) 201-209
    CrossrefPubMedGoogle Scholar
  • 23 You Y, Heo JS, Shin SH. et al. Optimal timing of portal vein embolization (PVE) after preoperative biliary drainage for hilar cholangiocarcinoma. HPB (Oxford) 2022; 24 (05) 635-644
    CrossrefPubMedGoogle Scholar
  • 24 Creasy JM, Sadot E, Koerkamp BG. et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery 2018; 163 (06) 1238-1244
    CrossrefPubMedGoogle Scholar
  • 25 Leung U, Kuk D, D'Angelica MI. et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015; 102 (01) 85-91
    CrossrefPubMedGoogle Scholar
  • 26 Lee DH, Kim JW, Lee JM. et al. Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma: comparison of treatment outcomes. Liver Cancer 2021; 10 (01) 25-37
    CrossrefPubMedGoogle Scholar
  • 27 Groeschl RT, Gamblin TC, Turaga KK. Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint. Ann Surg Oncol 2013; 20 (11) 3591-3595
    CrossrefPubMedGoogle Scholar
  • 28 Groeschl RT, Pilgrim CHC, Hanna EM. et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259 (06) 1195-1200
    CrossrefPubMedGoogle Scholar
  • 29 Puijk RS, Ruarus AH, Vroomen LGPH. et al; COLLISION Trial Group. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18 (01) 821
    CrossrefPubMedGoogle Scholar
  • 30 Tinguely P, Ruiter SJS, Engstrand J. et al. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Eur J Cancer 2023; 187: 65-76
    CrossrefPubMedGoogle Scholar
  • 31 White MJ, Nelson AT, Wothe J. et al. Feasibility of laparoscopic microwave ablation of caudate tumors: a case series. J Surg Case Rep 2023; 2023 (08) rjad478
    CrossrefPubMedGoogle Scholar
  • 32 Altman AM, Coughlan A, Shukla DM. et al. Minimally invasive microwave ablation provides excellent long-term outcomes for otherwise inaccessible hepatocellular cancer. J Surg Oncol 2020; 121 (08) 1218-1224
    CrossrefPubMedGoogle Scholar
  • 33 Lin MX, Ye JY, Tian WS. et al. Risk factors for bile duct injury after percutaneous thermal ablation of malignant liver tumors: a retrospective case-control study. Dig Dis Sci 2017; 62 (04) 1086-1094
    CrossrefPubMedGoogle Scholar
  • 34 Huang JW, Hernandez-Alejandro R, Croome KP. et al. Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol 2011; 17 (01) 123-129
    CrossrefPubMedGoogle Scholar
  • 35 Wada Y, Takami Y, Ryu T. et al. Predictive factors for local recurrence after intraoperative microwave ablation for colorectal liver metastases. Cancers (Basel) 2022; 15 (01) 122
    CrossrefPubMedGoogle Scholar
  • 36 McEachron KR, Ankeny JS, Robbins A. et al. Surgical microwave ablation of otherwise non-resectable colorectal cancer liver metastases: expanding opportunities for long term survival. Surg Oncol 2021; 36: 61-64
    CrossrefPubMedGoogle Scholar
  • 37 Huang X, Liu Y, Xu L. et al. Meta-analysis of percutaneous vs. surgical approaches radiofrequency ablation in hepatocellular carcinoma. Front Surg 2022; 8: 788771
    CrossrefPubMedGoogle Scholar
  • 38 Cassera MA, Potter KW, Ujiki MB, Swanström LL, Hansen PD. Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs. Surg Endosc 2011; 25 (04) 1088-1095
    CrossrefPubMedGoogle Scholar
  • 39 Puijk RS, Dijkstra M, van den Bemd BAT. et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the Prospective Amsterdam CORE Registry (AmCORE). Cardiovasc Intervent Radiol 2022; 45 (08) 1074-1089
    CrossrefPubMedGoogle Scholar
  • 40 Menahem B, Lubrano J, Duvoux C. et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta-analysis. Liver Transpl 2017; 23 (06) 836-844
    CrossrefPubMedGoogle Scholar
  • 41 Seshadri RM, Besur S, Niemeyer DJ. et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014; 16 (12) 1102-1109
    CrossrefPubMedGoogle Scholar
  • 42 Koh JH, Tan DJH, Ong Y. et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022; 11 (01) 78-93
    CrossrefPubMedGoogle Scholar
  • 43 Mahmud N. Selection for liver transplantation: indications and evaluation. Curr Hepatol Rep 2020; 19 (03) 203-212
    CrossrefPubMedGoogle Scholar
  • 44 Berry K, Ioannou GN. Comparison of liver transplant-related survival benefit in patients with versus without hepatocellular carcinoma in the United States. Gastroenterology 2015; 149 (03) 669-680 , quiz e15–e16
    CrossrefPubMedGoogle Scholar
  • 45 Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11 (03) 336-343
    CrossrefPubMedGoogle Scholar
  • 46 Kim WR, Biggins SW, Kremers WK. et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359 (10) 1018-1026
    CrossrefPubMedGoogle Scholar
  • 47 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 48 Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85
    PubMedGoogle Scholar
  • 49 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (08) 646-649
    CrossrefPubMedGoogle Scholar
  • 50 Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243 (03) 373-379
    CrossrefPubMedGoogle Scholar
  • 51 Hong SK, Lee KW, Hong SY. et al. Efficacy of liver resection for single large hepatocellular carcinoma in Child-Pugh A cirrhosis: analysis of a nationwide cancer registry database. Front Oncol 2021; 11: 674603
    CrossrefPubMedGoogle Scholar
  • 52 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedGoogle Scholar
  • 53 Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010; 42 (05) 341-347
    CrossrefPubMedGoogle Scholar
  • 54 Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol 2019; 11 (01) 1-18
    CrossrefPubMedGoogle Scholar
  • 55 Penzkofer L, Mittler J, Heinrich S. et al. Outcome after resection for hepatocellular carcinoma in noncirrhotic liver - a single centre study. J Clin Med 2022; 11 (19) 5802
    CrossrefPubMedGoogle Scholar
  • 56 Groot Koerkamp B, Wiggers JK, Allen PJ. et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg 2015; 221 (06) 1041-1049
    CrossrefPubMedGoogle Scholar
  • 57 Nooijen LE, Franssen S, Buis CI. et al. Long-term follow-up of a randomized trial of biliary drainage in perihilar cholangiocarcinoma. HPB (Oxford) 2023; 25 (02) 210-217
    CrossrefPubMedGoogle Scholar
  • 58 Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am 2009; 18 (02) 257-267 , viii
    CrossrefPubMedGoogle Scholar
  • 59 Olthof PB, Aldrighetti L, Alikhanov R. et al; Perihilar Cholangiocarcinoma Collaboration Group. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol 2020; 27 (07) 2311-2318
    CrossrefPubMedGoogle Scholar
  • 60 Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10 (03) 186-189
    CrossrefPubMedGoogle Scholar
  • 61 Rea DJ, Heimbach JK, Rosen CB. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242 (03) 451-458 , discussion 458–461
    CrossrefPubMedGoogle Scholar
  • 62 Oh DY, He AR, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) DOI: 10.1056/evidoa2200015.
    CrossrefPubMedGoogle Scholar
  • 63 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12 (10) 693-708
    CrossrefPubMedGoogle Scholar
  • 64 Rahbari NN, Biondo S, Feißt M. et al. Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. J Clin Oncol 2022; 40 (17) LBA3507-LBA3507
    CrossrefPubMedGoogle Scholar
  • 65 Kanemitsu Y, Shitara K, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 2021; 39 (10) 1098-1107
    CrossrefPubMedGoogle Scholar
  • 66 Feo L, Polcino M, Nash GM. Resection of the primary tumor in stage IV colorectal cancer: When is it necessary?. Surg Clin North Am 2017; 97 (03) 657-669
    CrossrefPubMedGoogle Scholar
  • 67 Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014; 21 (02) 501-506
    CrossrefPubMedGoogle Scholar
  • 68 Srouji R, Narayan R, Boerner T. et al. Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver-related mortality. J Surg Oncol 2020; 121 (08) 1314-1319
    CrossrefPubMedGoogle Scholar
  • 69 Nordlinger B, Sorbye H, Glimelius B. et al; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14 (12) 1208-1215
    CrossrefPubMedGoogle Scholar
  • 70 Kanemitsu Y, Shimizu Y, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol 2021; 39 (34) 3789-3799
    CrossrefPubMedGoogle Scholar
  • 71 Engstrand J, Sterner J, Hasselgren K, Stromberg C, Sturesson C. Treatment intention and outcome in patients with simultaneously diagnosed liver and lung metastases from colorectal cancer. Eur J Surg Oncol 2022; 48 (08) 1799-1806
    CrossrefPubMedGoogle Scholar
  • 72 Tran TB, Worhunsky DJ, Spain DA. et al. The significance of underlying cardiac comorbidity on major adverse cardiac events after major liver resection. HPB (Oxford) 2016; 18 (09) 742-747
    CrossrefPubMedGoogle Scholar
  • 73 Hallet J, Tillman B, Zuckerman J. et al; Members of the Recovery after Surgical Therapy for Older Adults Research–Cancer (RESTORE-Cancer) Group. Association between frailty and time alive and at home after cancer surgery among older adults: a population-based analysis. J Natl Compr Canc Netw 2022; 20 (11) 1223-1232.e8
    CrossrefPubMedGoogle Scholar
  • 74 Liu TS, Shen QH, Zhou XY. et al. Application of controlled low central venous pressure during hepatectomy: a systematic review and meta-analysis. J Clin Anesth 2021; 75: 110467
    CrossrefPubMedGoogle Scholar
  • 75 Melendez JA, Arslan V, Fischer ME. et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998; 187 (06) 620-625
    CrossrefPubMedGoogle Scholar
  • 76 Yu L, Sun H, Jin H, Tan H. The effect of low central venous pressure on hepatic surgical field bleeding and serum lactate in patients undergoing partial hepatectomy: a prospective randomized controlled trial. BMC Surg 2020; 20 (01) 25
    CrossrefPubMedGoogle Scholar
  • 77 O'Connor DC, Seier K, Gonen M. et al. Invasive central venous monitoring during hepatic resection: unnecessary for most patients. HPB (Oxford) 2020; 22 (12) 1732-1737
    CrossrefPubMedGoogle Scholar
  • 78 Jongerius IM, Mungroop TH, Uz Z. et al. Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO): a surgeon- and patient-blinded randomized controlled trial. HPB (Oxford) 2021; 23 (10) 1578-1585
    CrossrefPubMedGoogle Scholar
  • 79 Ratti F, Cipriani F, Reineke R. et al. Intraoperative monitoring of stroke volume variation versus central venous pressure in laparoscopic liver surgery: a randomized prospective comparative trial. HPB (Oxford) 2016; 18 (02) 136-144
    CrossrefPubMedGoogle Scholar
  • 80 Yang Y, Liu F, Yu J. et al. Risk factor analysis of acute kidney injury after microwave ablation of hepatocellular carcinoma: a retrospective study. Front Oncol 2020; 10: 1408
    CrossrefPubMedGoogle Scholar
  • 81 Li D, Yu J, Han Z. et al. Risk factors of haemoglobinuria after microwave ablation of liver tumours. Clin Radiol 2018; 73 (11) 982.e9-982.e15
    CrossrefPubMedGoogle Scholar
  • 82 Joliat GR, Kobayashi K, Hasegawa K. et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022. World J Surg 2023; 47 (01) 11-34
    CrossrefPubMedGoogle Scholar
  • 83 Jin S, Fu Q, Wuyun G, Wuyun T. Management of post-hepatectomy complications. World J Gastroenterol 2013; 19 (44) 7983-7991
    CrossrefPubMedGoogle Scholar
  • 84 Sultana A, Brooke-Smith M, Ullah S. et al. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB (Oxford) 2018; 20 (05) 462-469
    CrossrefPubMedGoogle Scholar
  • 85 Lee KF, Lo EYJ, Wong KKC. et al. Acute kidney injury following hepatectomy and its impact on long-term survival for patients with hepatocellular carcinoma. BJS Open 2021; 5 (05) 77
    PubMedGoogle Scholar
  • 86 Rahbari NN, Garden OJ, Padbury R. et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011; 149 (05) 713-724
    CrossrefPubMedGoogle Scholar
  • 87 Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF) - recent advances in prevention and clinical management. Eur J Surg Oncol 2021; 47 (02) 216-224
    CrossrefPubMedGoogle Scholar